Novartis announced today that the US Food and Drug Administration (FDA) has granted priority review for Coartem® (artemether 20 mg/lumefantrine 120 mg), the leading artemisinin-based combination treatment (ACT) for malaria worldwide. Recommended by the World Health Organization (WHO) and widely used in Africa, Coartem could become the first ACT approved for use by the FDA.
The details can be read here.
No comments:
Post a Comment